When administered by licensed clinicians, IV GSH is generally well tolerated
Related Diabetes and SGLT2 Inhibitor Choices Jardiance belongs to the SGLT2 inhibitor class
Decrease dose consideration: Persistent side effects including headaches, fatigue, or injection site reactions, excessive response (extremely rapid weight loss suggesting dose may be higher than needed), cost concerns when lower doses might achieve similar results
In addition to therapeutic prospects, this study underscores the transformative potential of harnessing large-scale, real-world clinical data to uncover unanticipated drug benefits
The statistics are compelling: worldwide, nearly 4 million people die each year due to overweight or obesity-related causes, highlighting the pressing need for innovative solutions